Allergan 100 Vials - Allergan Refresh Plus Lubricant Eye Drops Single-Use Vials - 100 Ct.

Product Information

Still, issues can come up with sterility. “This is a bit concerning,” says Mina Massaro-Gordon, M.D., a professor of clinical ophthalmology at the University of Pennsylvania. In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache. If you have any of these eye drops at home, the FDA recommends getting rid of them. If you’ve already used them and develop signs of an eye infection, the agency says it’s important to talk to your healthcare provider or seek medical care “immediately.” Adverse reactions reported by greater than 2% of patients in the first 6 months following injection of OZURDEX ® for retinal vein occlusion and posterior segment uveitis include: intraocular pressure increased (25%), conjunctival hemorrhage (22%), eye pain (8%), conjunctival hyperemia (7%), ocular hypertension (5%), cataract (5%), vitreous detachment (2%), and headache (4%). The development of secondary ocular infection (bacterial, fungal, and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used.

The most common adverse reactions (>5%) reported in clinical trials were headache, conjunctival hyperemia, and eye irritation. VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens. Leader’s drops were included in the October recall over concerns about sterility and bacterial contamination. Information for Patients: Advise patients that if eye inflammation or pain persists longer than 48 hours or becomes aggravated, they should consult a physician. Nursing Mothers: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Carousel 9

Brimonidine Tartrate Ophthalmic Solution, 0.15%, NDC numbers 60505-0564-1, 60505-0564-2 and 60505-0564-3. The biggest concern is about post-infection corneal scarring, Zimmerman says. “This scarring can substantially impair vision and may result in a corneal transplant,” he points out. “If identified early and proper treatment occurs, then the risk of post-infectious scarring is much lower than if it were delayed.” RESTASIS ® and RESTASIS MULTIDOSE ® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation. COMBIGAN ® may reduce blood pressure. Use caution in patients on antihypertensives and/or cardiac glycosides.

Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN ® P in humans can lead to resulting interference with the IOP-lowering effect. Use caution in patients on tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines. In May, the Centers for Disease Control and Prevention (CDC) noted 81 patients in 18 states with VIM-GES-CRPA, a rare strain of the drug-resistant Pseudomonas aeruginosa. Certain types of artificial tears have been named as a common exposure for many patients. So far, 14 patients have gone blind and an additional four had to have their eyeballs surgically removed.Despite these disturbing numbers, doctors stress that eye drop recalls have not been common in the past, and they’re incredibly rare in known brand names. “The vast majority of products available on the shelves in the United States are cleared by the FDA and subject to investigations if there is a safety issue with a product,” says Zimmerman. Increased Intraocular Pressure: IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 28% of OZURDEX ® patients versus 4% of sham patients. 42% of the patients who received OZURDEX ® were subsequently treated with IOP-lowering medications during the study versus 10% of sham patients. Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA ® intracameral implant. DURYSTA ® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Antihypertensives/Cardiac Glycosides: ALPHAGAN ® P may reduce blood pressure. Use caution in patients on antihypertensives and/or cardiac glycosides. COMBIGAN ® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of COMBIGAN ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day.

DURYSTA ® should be used with caution in patients with narrow iridocorneal angles (Shaffer grade ˂ 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle. RESTASIS ® and RESTASIS MULTIDOSE ® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/zymaxid_pi.pdf

Carousel 3

Bimatoprost ophthalmic solution has been reported to cause changes to pigmented ZYMAXID is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication. ALPHAGAN ® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The XEN ® Glaucoma Treatment System (XEN ® 45 Gel Stent preloaded into a XEN ® Injector) is indicated for the management of refractory glaucomas, including cases where previous surgical treatment has failed, cases of primary open-angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.

Low blood pressure, swelling or coldness of your hands, feet and extremities, caused by constriction of your blood vessels Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml. On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml usage, the most frequently reported adverse reactions were: Prostaglandin analogues including LUMIGAN can induce periorbital lipodystrophic changes which can lead to deepening of the eyelid sulcus, ptosis, enophthalmos, eyelid retraction, involution of dermatochalasis and inferior scleral show. Changes are typically mild, can occur as early as one month after initiation of treatment with LUMIGAN, and may cause impaired field of vision even in the absence of patient recognition. PAP is also associated with periocular skin hyperpigmentation or discoloration and hypertrichosis. All changes have been noted to be partially or fully reversible upon discontinuation or switch to alternative treatments. OZURDEX ® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema.

Fact Box

punctate keratitis, eye irritation, eye pruritus, growth of eyelashes, eye pain, erythema of eyelid, eyelid pruritus Ophthalmic bimatoprost, including DURYSTA ® intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA ® can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. If you have symptoms of an eye infection, Zimmerman says it’s important to seek care from an optometrist or ophthalmologist. “These individuals are trained and deal with eye infections regularly,” he says. “They can differentiate between viral, bacterial, and other infectious microbes and then treat them appropriately.” How to treat an eye infection Increased Bleeding Time: With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. ACUVAIL solution should be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.